vs
MADRIGAL PHARMACEUTICALS, INC.（MDGL）与医疗房产信托（SVC）财务数据对比。点击上方公司名可切换其他公司
MADRIGAL PHARMACEUTICALS, INC.的季度营收约是医疗房产信托的1.1倍（$321.1M vs $296.5M），医疗房产信托净利率更高（-0.3% vs -18.2%，领先18.0%），MADRIGAL PHARMACEUTICALS, INC.同比增速更快（210.8% vs -17.0%），医疗房产信托自由现金流更多（$-95.2M vs $-133.8M）
本公司是一家美国生物制药企业，成立于2002年，专注于研发新型合成胆汁酸类似物，可用于治疗原发性胆汁性胆管炎、非酒精性脂肪肝、肝硬化等慢性肝病，以及胆汁酸性腹泻等肠道疾病。
医疗房产信托（MPT）是总部位于阿拉巴马州伯明翰的国际房地产投资信托（REIT），主要在美国和欧洲地区收购投资医疗设施与营利性医疗控股公司。该公司的房产收购多采用售后回租模式，原产权方出售房产给MPT后成为承租租户，其租户普遍签订长期三净租约。
MDGL vs SVC — 直观对比
营收规模更大
MDGL
是对方的1.1倍
$296.5M
营收增速更快
MDGL
高出227.7%
-17.0%
净利率更高
SVC
高出18.0%
-18.2%
自由现金流更多
SVC
多$38.7M
$-133.8M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $321.1M | $296.5M |
| 净利润 | $-58.6M | $-782.0K |
| 毛利率 | — | — |
| 营业利润率 | -18.6% | -3.9% |
| 净利率 | -18.2% | -0.3% |
| 营收同比 | 210.8% | -17.0% |
| 净利润同比 | 1.4% | 99.0% |
| 每股收益（稀释后） | $-2.55 | $-0.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MDGLSVC
| Q4 25 | $321.1M | $296.5M | ||
| Q3 25 | $287.3M | $377.6M | ||
| Q2 25 | $212.8M | $404.4M | ||
| Q1 25 | $137.3M | $335.0M | ||
| Q4 24 | $103.3M | $357.0M | ||
| Q3 24 | $62.2M | $390.9M | ||
| Q2 24 | — | $412.5M | ||
| Q1 24 | $0 | $336.2M |
净利润MDGLSVC
| Q4 25 | $-58.6M | $-782.0K | ||
| Q3 25 | $-114.2M | $-46.9M | ||
| Q2 25 | $-42.3M | $-38.2M | ||
| Q1 25 | $-73.2M | $-116.4M | ||
| Q4 24 | $-59.4M | $-76.4M | ||
| Q3 24 | $-107.0M | $-46.9M | ||
| Q2 24 | — | $-73.8M | ||
| Q1 24 | $-147.5M | $-78.4M |
毛利率MDGLSVC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 96.7% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率MDGLSVC
| Q4 25 | -18.6% | -3.9% | ||
| Q3 25 | -39.7% | -12.8% | ||
| Q2 25 | -22.2% | -9.2% | ||
| Q1 25 | -57.8% | -33.3% | ||
| Q4 24 | -64.8% | -19.4% | ||
| Q3 24 | -187.1% | -12.8% | ||
| Q2 24 | — | -17.1% | ||
| Q1 24 | — | -21.4% |
净利率MDGLSVC
| Q4 25 | -18.2% | -0.3% | ||
| Q3 25 | -39.8% | -12.4% | ||
| Q2 25 | -19.9% | -9.4% | ||
| Q1 25 | -53.4% | -34.8% | ||
| Q4 24 | -57.5% | -21.4% | ||
| Q3 24 | -172.0% | -12.0% | ||
| Q2 24 | — | -17.9% | ||
| Q1 24 | — | -23.3% |
每股收益（稀释后）MDGLSVC
| Q4 25 | $-2.55 | $-0.01 | ||
| Q3 25 | $-5.08 | $-0.28 | ||
| Q2 25 | $-1.90 | $-0.23 | ||
| Q1 25 | $-3.32 | $-0.70 | ||
| Q4 24 | $-2.50 | $-0.46 | ||
| Q3 24 | $-4.92 | $-0.28 | ||
| Q2 24 | — | $-0.45 | ||
| Q1 24 | $-7.38 | $-0.48 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $198.7M | $346.8M |
| 总债务越低越好 | $339.9M | $5.5B |
| 股东权益账面价值 | $602.7M | $646.1M |
| 总资产 | $1.3B | $6.5B |
| 负债/权益比越低杠杆越低 | 0.56× | 8.52× |
8季度趋势，按日历期对齐
现金及短期投资MDGLSVC
| Q4 25 | $198.7M | $346.8M | ||
| Q3 25 | $295.7M | $417.4M | ||
| Q2 25 | $186.2M | $63.2M | ||
| Q1 25 | $183.6M | $80.1M | ||
| Q4 24 | $100.0M | $143.5M | ||
| Q3 24 | $232.7M | $48.6M | ||
| Q2 24 | — | $14.6M | ||
| Q1 24 | $622.5M | $71.3M |
总债务MDGLSVC
| Q4 25 | $339.9M | $5.5B | ||
| Q3 25 | $339.8M | — | ||
| Q2 25 | $118.4M | — | ||
| Q1 25 | $118.0M | — | ||
| Q4 24 | $117.6M | $5.8B | ||
| Q3 24 | $117.1M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $116.1M | — |
股东权益MDGLSVC
| Q4 25 | $602.7M | $646.1M | ||
| Q3 25 | $625.7M | $647.9M | ||
| Q2 25 | $696.0M | $695.9M | ||
| Q1 25 | $710.6M | $734.6M | ||
| Q4 24 | $754.4M | $851.9M | ||
| Q3 24 | $777.2M | $929.0M | ||
| Q2 24 | — | $1.0B | ||
| Q1 24 | $850.8M | $1.1B |
总资产MDGLSVC
| Q4 25 | $1.3B | $6.5B | ||
| Q3 25 | $1.4B | $7.0B | ||
| Q2 25 | $1.0B | $6.9B | ||
| Q1 25 | $996.6M | $7.0B | ||
| Q4 24 | $1.0B | $7.1B | ||
| Q3 24 | $1.1B | $7.1B | ||
| Q2 24 | — | $7.1B | ||
| Q1 24 | $1.1B | $7.2B |
负债/权益比MDGLSVC
| Q4 25 | 0.56× | 8.52× | ||
| Q3 25 | 0.54× | — | ||
| Q2 25 | 0.17× | — | ||
| Q1 25 | 0.17× | — | ||
| Q4 24 | 0.16× | 6.85× | ||
| Q3 24 | 0.15× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.14× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-133.5M | $-18.5M |
| 自由现金流经营现金流 - 资本支出 | $-133.8M | $-95.2M |
| 自由现金流率自由现金流/营收 | -41.7% | -32.1% |
| 资本支出强度资本支出/营收 | 0.1% | 25.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-107.0M |
8季度趋势，按日历期对齐
经营现金流MDGLSVC
| Q4 25 | $-133.5M | $-18.5M | ||
| Q3 25 | $79.8M | $98.1M | ||
| Q2 25 | $-47.1M | $-7.0K | ||
| Q1 25 | $-88.9M | $38.2M | ||
| Q4 24 | $-104.5M | $-9.7M | ||
| Q3 24 | $-67.0M | $106.2M | ||
| Q2 24 | — | $43.8M | ||
| Q1 24 | $-149.2M | $-926.0K |
自由现金流MDGLSVC
| Q4 25 | $-133.8M | $-95.2M | ||
| Q3 25 | $79.0M | $57.9M | ||
| Q2 25 | — | $-46.6M | ||
| Q1 25 | — | $-23.2M | ||
| Q4 24 | $-104.7M | $-88.9M | ||
| Q3 24 | $-67.8M | $24.1M | ||
| Q2 24 | — | $-22.3M | ||
| Q1 24 | $-149.5M | $-77.2M |
自由现金流率MDGLSVC
| Q4 25 | -41.7% | -32.1% | ||
| Q3 25 | 27.5% | 15.3% | ||
| Q2 25 | — | -11.5% | ||
| Q1 25 | — | -6.9% | ||
| Q4 24 | -101.3% | -24.9% | ||
| Q3 24 | -109.0% | 6.2% | ||
| Q2 24 | — | -5.4% | ||
| Q1 24 | — | -23.0% |
资本支出强度MDGLSVC
| Q4 25 | 0.1% | 25.9% | ||
| Q3 25 | 0.3% | 10.6% | ||
| Q2 25 | 0.0% | 11.5% | ||
| Q1 25 | 0.0% | 18.3% | ||
| Q4 24 | 0.2% | 22.2% | ||
| Q3 24 | 1.3% | 21.0% | ||
| Q2 24 | — | 16.0% | ||
| Q1 24 | — | 22.7% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MDGL
| Rebates Customer Fees Credits Co Pay Assistance And Other | $208.5M | 65% |
| Other | $76.0M | 24% |
| Chargebacks Discounts For Prompt Pay And Other Allowances | $36.6M | 11% |
SVC
暂无分部数据
